This website has been produced and funded by Novo Nordisk and is intended for adult patients in
the United Kingdom who have been prescribed Wegovy®▼ (semaglutide injection). Side effect reporting
information can be found in the footer of this page.
How does Wegovy®▼ (semaglutide injection) work?
Normally, your body sends signals to your brain to tell you that you are hungry or that you crave certain foods. These signals are called appetite hormones.
After you finish eating, your body releases a gut hormone called ‘GLP-1’ (glucagon-like peptide-1).
Wegovy® is a type of medicine called a ‘GLP-1 agonist’. The active substance (main ingredient) of Wegovy®, semaglutide, mimics how GLP-1 works in the body. It acts on the parts of the brain that control your appetite.
This is not a real patient and is for illustrative purposes only.
For weight management
Wegovy® works by helping you to feel fuller so that you feel less hungry and experience fewer cravings.
Wegovy® is prescribed along with diet and exercise for weight loss and weight maintenance in:
- Adults with obesity (Body Mass Index (BMI)* of 30 kg/m2 or greater)
- Adults who are overweight (a BMI* of 27 kg/m2 and less than 30 kg/m2) and have weight-related health problems
*BMI is a measure of your weight in relation to your height.
This is not a real patient and is for illustrative purposes only.
For risk reduction of serious heart issues (cardiovascular risk reduction)
The exact way Wegovy® lowers the risk of serious heart issues isn’t fully understood.
Wegovy® is used along with diet and exercise to reduce the risk of serious heart issues (heart-related death, heart attacks and strokes) in adults with a history of heart disease (like a heart attack, stroke or poor blood flow to the limbs) and either obesity or overweight (BMI* ≥27 kg/m2).
*BMI is a measure of your weight in relation to your height.
The information on this website does not replace the Patient Information Leaflet (PIL), which you are advised to read in full. It is not intended as a substitute for clinical advice provided by your healthcare professional. Please contact your healthcare professional if you have any questions about your treatment and for clinical advice. Please refer to the PIL found in the product carton for further information on Wegovy®, further information on how to use Wegovy® and a full list of side effects, warnings and precautions.
Reporting side effects
▼This medicine is subject to additional monitoring. This will allow quick identification of new safety information promptly. You can help by reporting any side effects you may get. See https://yellowcard.mhra.gov.uk/ for how to report side effects.
If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in the package leaflet. You can also report side effects directly via the Yellow Card Scheme at https://yellowcard.mhra.gov.uk/. Side effects should also be reported to Novo Nordisk Limited (Telephone Novo Nordisk Customer Care Centre 0800 023 2573). Calls may be monitored for training purposes. By reporting side effects, you can help provide more information on the safety of this medicine.